Zheng Wei, Wang Renfei, Tan Jian, Li Ning, Meng Zhaowei
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Mol Med Rep. 2017 Apr;15(4):1471-1478. doi: 10.3892/mmr.2017.6181. Epub 2017 Feb 8.
The present study aimed to develop a stable Graves' disease (GD) model in BALB/c mice by immunization and electroporation (EP). A total of 90 mice were divided into experimental (n=50), control (n=20) and blank (n=20) groups. The recombinant plasmid pcDNA3.1/thyroid‑stimulating hormone (TSH) receptor 268 was constructed and injected into the bilateral gastrocnemius of experimental group mice at weeks 1, 4, 7 and 10. Equal volumes of saline were injected into the control and blank groups at the same time. The experimental and control groups were subjected to EP at the same time and location to enhance immunization. The levels of total serum thyroxine (T4) and serum TSH were examined by radioimmunoassay and immunoradiometric assay, respectively. The levels of serum thyrotropin receptor N‑terminal (TRAb N) and C‑terminal (TRAb C) antibodies were assessed by ELISA. Whole body pertechnetate (99mTcO4‑) imaging was performed. Mouse weight and thyroid morphology and pathology were analyzed. The GD BALB/c mouse model was successfully established, with a positive rate of 79.17% (38/48). T4 levels increased from baseline levels of 12.05±4.23 to 52.51±23.58 ng/ml by week 12 (P<0.0001). TSH levels decreased from baseline levels of 5.53±2.78 to 1.43±0.89 µIU/ml by week 12 (P<0.0001). TRAb N antibody levels increased from baseline levels of 0.006±0.002 to 0.278±0.106 mIU/ml by week 12 (P<0.0001). TRAb C antibody levels increased from baseline levels of 11.111±2.808 to 46.701±26.436 arbitrary units/ml by week 12 (P<0.0001). At week 21, TSH levels remained reduced compared with pre‑immunization levels (P<0.0001). Although T4, and TRAb N and C levels decreased, they remained increased compared with preimmunization levels (P<0.0001, P<0.0001, P=0.001). There were no significant alterations in antibody levels between the control and blank groups. Following four immunizations, the uptake of 99mTcO4‑ by the thyroid was significantly increased in the experimental group. The mean weight of the experimental mice was significantly reduced compared with the control and blank groups (all P<0.0001). Furthermore, the thyroid glands of the immunized mice were enlarged and exhibited lymphocyte infiltration, fewer colloid nodules and an increased height of epithelial cells. In conclusion, by injecting recombinant plasmid pcDNA3.1/TSHR268 and EP, a GD mouse model was successfully established.
本研究旨在通过免疫和电穿孔(EP)在BALB/c小鼠中建立稳定的格雷夫斯病(GD)模型。总共90只小鼠被分为实验组(n = 50)、对照组(n = 20)和空白组(n = 20)。构建重组质粒pcDNA3.1/促甲状腺激素(TSH)受体268,并在第1、4、7和10周注射到实验组小鼠的双侧腓肠肌中。同时向对照组和空白组注射等量的生理盐水。实验组和对照组在同一时间和位置进行电穿孔以增强免疫。分别通过放射免疫分析和免疫放射分析检测血清总甲状腺素(T4)和血清TSH水平。通过酶联免疫吸附测定评估血清促甲状腺素受体N端(TRAb N)和C端(TRAb C)抗体水平。进行全身高锝酸盐(99mTcO4-)显像。分析小鼠体重以及甲状腺的形态和病理。成功建立了GD BALB/c小鼠模型,阳性率为79.17%(38/48)。到第12周时,T4水平从基线水平12.05±4.23 ng/ml升高至52.51±23.58 ng/ml(P<0.0001)。TSH水平从基线水平5.53±2.78 μIU/ml降至第12周时的1.43±0.89 μIU/ml(P<0.0001)。到第12周时,TRAb N抗体水平从基线水平0.006±0.002 mIU/ml升高至0.278±0.106 mIU/ml(P<0.0001)。TRAb C抗体水平从基线水平11.111±2.808任意单位/ml升高至第12周时的46.701±26.436任意单位/ml(P<0.0001)。在第21周时,TSH水平与免疫前水平相比仍降低(P<0.0001)。尽管T4以及TRAb N和C水平有所下降,但与免疫前水平相比仍升高(P<0.0001、P<0.0001、P = 0.001)。对照组和空白组之间抗体水平无显著变化。经过四次免疫后,实验组甲状腺对99mTcO4-的摄取显著增加。与对照组和空白组相比,实验小鼠的平均体重显著降低(均P<0.0001)。此外,免疫小鼠的甲状腺肿大,表现出淋巴细胞浸润、胶体结节减少以及上皮细胞高度增加。总之,通过注射重组质粒pcDNA3.1/TSHR268和电穿孔,成功建立了GD小鼠模型。